Benay Taub Lung Cancer Research Act
Summary
HR6319 is an early-stage bill that establishes a Lung Cancer Task Force within NIH to study research disparities, funding levels, and screenings. It authorizes no funding and creates no direct revenue or cost impact on any publicly traded company. No market action is justified at this stage.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.Zero funding or spending authorized — no money trail for investors
- 2.Merely establishes a study task force with no binding recommendations
- 3.Early procedural stage with no committee action since Nov 2025
- 4.No identified tickers — no causal chain from bill text to any public company revenue
Market Implications
No market implications. HR6319 is a study-authorization bill with zero appropriations. It does not change the competitive dynamics, revenue outlook, or regulatory burden for any publicly traded company in lung cancer diagnostics, therapeutics, or screening. Retail investors should ignore this legislation until and unless it advances to a funding stage.
Full Analysis
- On November 28, 2025, Rep. Gottheimer (D-NJ) introduced HR6319, the Benay Taub Lung Cancer Research Act. It was immediately referred to the House Committee on Energy and Commerce and has had no further action since referral. The bill is in its earliest legislative stage with zero committee hearings, markups, or votes. 2) The bill text creates a task force within NIH to examine lung cancer research disparities relative to other diseases, federal funding levels, and screening rates. It does not authorize or appropriate any dollar amount. The task force must report findings and recommendations to Congress within 180 days of enactment. There is no procurement mandate, no grant program, no tax credit, and no regulatory requirement directed at private companies. 3) Without funding or any binding directive, there are no structural winners or losers in publicly traded equities. Companies with exposure to lung cancer diagnostics, therapeutics, or screening technology — such as $LLY (oncology pipeline), $JNJ (lung cancer drugs), $BMY (Opdivo), $MRK (Keytruda), or screening firms like $ILMN (genomic sequencing) — have zero direct revenue channel from this procedural bill. 4) The bill has only 4 cosponsors, all junior members, and sits in the Commerce Committee. No companion bill exists in the Senate. Legislative velocity is minimal. 5) Remaining steps: committee consideration, potential markup, House vote, Senate introduction/passage, presidential signature. Given the procedural nature and zero funding authorization, this bill has effectively no timeline pressure or market relevance for at least 12-18 months, if ever.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Women and Lung Cancer Research and Preventive Services Act of 2025
Lung Cancer Screening Expansion Act of 2025
Women and Lung Cancer Research and Preventive Services Act of 2025
Increasing Access to Lung Cancer Screening Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Accelerating Access To Veterans' Benefits And Employment Opportunities
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →